Stocks
Allogene Therapeutics (ALLO) Debt/EBITDA US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | 2.26 | 1.30 | 1.13 | 0.83 | 0.90 | 0.92 | |||
| Changes by years, y/y, % | -42% | -43% | -13% | -27% | +9% | -25.4% | |||
Allogene Therapeutics. Debt/EBITDA
Allogene Therapeutics. Debt/EBITDA, changes, %
Allogene Therapeutics (ALLO) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | LTM ? | |||
| Debt/EBITDA | 0.83 | 0.83 | 0.87 | 0.84 | 0.92 | 0.92 | ||
| Changes by years, y/y, % | -30% | -23% | -38% | +4% | +11% | |||
| Changes by quarters, q/q, % | +3% | +1% | +4% | -3% | +9% | |||
